Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $58 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts BHVN Hot Sheet
Price: $15.42 -6.49%
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $58.00 (from $75.00) while maintaining a Buy rating.
You May Also Be Interested In
- Biohaven Pharma (BHVN) PT Raised to $32 at Canaccord
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- e.l.f. Beauty (ELF) PT Raised to $100 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
